NCT02078102View on ClinicalTrials.gov

A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

March 11, 2014

Primary Completion Date

November 6, 2018

Study Completion Date

February 21, 2019

Conditions
Multiple MyelomaNon-Hodgkin's Lymphoma
Interventions
DRUG

Meloxicam

15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.

DRUG

Filgrastim

Filgrastim will be subcutaneously injected in one or two sites at home.

Trial Locations (1)

46202

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sherif S. Farag

OTHER

NCT02078102 - A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter